Unity Total Assets from 2010 to 2025

UBX Stock

USD 1.83 0.13 7.65%

Unity Biotechnology Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 35.8 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2016-12-31

Previous Quarter

47.1 M

Current Value

37.7 M

Quarterly Volatility

44.8 M

Covid

Check Unity Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unity Biotechnology's main balance sheet or income statement drivers, such as Net Interest Income of 1.8 M, Interest Income of 1.5 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 104, Dividend Yield of 0.0 or PTB Ratio of 2.66. Unity financial statements analysis is a perfect complement when working with Unity Biotechnology Valuation or Volatility modules.

Check out the analysis of Unity Biotechnology Correlation against competitors.

For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.

Latest Unity Biotechnology's Total Assets Growth Pattern

Below is the plot of the Total Assets of Unity Biotechnology over the last few years. Total assets refers to the total amount of Unity Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Unity Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Unity Biotechnology's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unity Biotechnology's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 37.66 M

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Total Assets

Timeline

Unity Total Assets Regression Statistics

	Arithmetic Mean	103,479,244
	Geometric Mean	95,428,333
	Coefficient Of Variation	37.59
	Mean Deviation	27,572,598
	Median	96,648,000
	Standard Deviation	38,899,472
	Sample Variance	1513.2T
	Range	145.6M
	R-Value	(0.19)
	Mean Square Error	1565.2T
	R-Squared	0.03
	Significance	0.49
	Slope	(1,519,414)
	Total Sum of Squares	22697.5T

Unity Total Assets History

	2025	35.8 M
	2024	37.7 M
	2023	65.7 M
	2022	124.3 M
	2021	124.7 M
	2020	156.3 M
	2019	151.2 M

Other Fundumenentals of Unity Biotechnology

Intangibles To Total Assets

Unity Biotechnology Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Receivables	Long Term Debt Total	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt	Long Term Debt	Short Long Term Debt
Total Assets		0.64	0.37	0.09	0.23	0.68	-0.1	-0.11	0.93	0.53	0.3	-0.81	0.2	0.92	0.91	-0.04	0.51	0.33	-0.07	0.51	-0.53
Total Stockholder Equity	0.64		0.74	0.69	-0.41	0.89	0.51	-0.84	0.45	0.77	0.51	-0.75	0.52	0.38	0.44	0.44	0.1	0.25	0.27	-0.1	0.06
Net Tangible Assets	0.37	0.74		0.68	-0.69	0.71	0.81	-0.69	0.18	0.63	0.54	-0.66	0.68	0.06	0.14	0.69	-0.11	0.26	0.43	-0.42	0.38
Net Debt	0.09	0.69	0.68		-0.88	0.38	0.88	-0.82	-0.23	0.6	0.71	-0.5	0.68	-0.28	-0.26	0.8	-0.27	0.44	0.76	-0.65	0.57
Retained Earnings	0.23	-0.41	-0.69	-0.88		-0.18	-0.98	0.69	0.51	-0.4	-0.57	0.28	-0.69	0.59	0.54	-0.9	0.46	-0.23	-0.8	0.88	-0.79
Accounts Payable	0.68	0.89	0.71	0.38	-0.18		0.33	-0.65	0.6	0.73	0.38	-0.73	0.47	0.52	0.59	0.25	0.28	0.13	-0.02	0.16	-0.17
Capital Surpluse	-0.1	0.51	0.81	0.88	-0.98	0.33		-0.73	-0.37	0.51	0.62	-0.41	0.71	-0.46	-0.4	0.88	-0.36	0.24	0.76	-0.8	0.7
Total Liab	-0.11	-0.84	-0.69	-0.82	0.69	-0.65	-0.73		0.07	-0.61	-0.44	0.38	-0.53	0.16	0.08	-0.6	0.24	-0.09	-0.39	0.5	-0.47
Total Current Assets	0.93	0.45	0.18	-0.23	0.51	0.6	-0.37	0.07		0.28	-0.04	-0.6	-0.12	0.99	1.0	-0.35	0.49	0.04	-0.33	0.66	-0.65
Common Stock	0.53	0.77	0.63	0.6	-0.4	0.73	0.51	-0.61	0.28		0.85	-0.73	0.65	0.25	0.27	0.51	0.55	0.42	0.21	0.04	-0.19
Property Plant Equipment	0.3	0.51	0.54	0.71	-0.57	0.38	0.62	-0.44	-0.04	0.85		-0.64	0.78	-0.04	-0.08	0.68	0.39	0.7	0.49	-0.16	0.0
Net Receivables	-0.81	-0.75	-0.66	-0.5	0.28	-0.73	-0.41	0.38	-0.6	-0.73	-0.64		-0.54	-0.56	-0.55	-0.4	-0.33	-0.38	-0.44	-0.07	0.19
Long Term Debt Total	0.2	0.52	0.68	0.68	-0.69	0.47	0.71	-0.53	-0.12	0.65	0.78	-0.54		-0.14	-0.15	0.88	0.04	0.58	0.47	-0.35	0.31
Net Invested Capital	0.92	0.38	0.06	-0.28	0.59	0.52	-0.46	0.16	0.99	0.25	-0.04	-0.56	-0.14		0.99	-0.41	0.55	0.12	-0.37	0.75	-0.72
Net Working Capital	0.91	0.44	0.14	-0.26	0.54	0.59	-0.4	0.08	1.0	0.27	-0.08	-0.55	-0.15	0.99		-0.4	0.5	0.03	-0.38	0.69	-0.67
Deferred Long Term Liab	-0.04	0.44	0.69	0.8	-0.9	0.25	0.88	-0.6	-0.35	0.51	0.68	-0.4	0.88	-0.41	-0.4		-0.25	0.36	0.71	-0.72	0.64
Capital Stock	0.51	0.1	-0.11	-0.27	0.46	0.28	-0.36	0.24	0.49	0.55	0.39	-0.33	0.04	0.55	0.5	-0.25		0.23	-0.43	0.76	-0.87
Current Deferred Revenue	0.33	0.25	0.26	0.44	-0.23	0.13	0.24	-0.09	0.04	0.42	0.7	-0.38	0.58	0.12	0.03	0.36	0.23		0.21	0.1	-0.09
Short Term Debt	-0.07	0.27	0.43	0.76	-0.8	-0.02	0.76	-0.39	-0.33	0.21	0.49	-0.44	0.47	-0.37	-0.38	0.71	-0.43	0.21		-0.75	0.62
Long Term Debt	0.51	-0.1	-0.42	-0.65	0.88	0.16	-0.8	0.5	0.66	0.04	-0.16	-0.07	-0.35	0.75	0.69	-0.72	0.76	0.1	-0.75		-0.96
Short Long Term Debt	-0.53	0.06	0.38	0.57	-0.79	-0.17	0.7	-0.47	-0.65	-0.19	0.0	0.19	0.31	-0.72	-0.67	0.64	-0.87	-0.09	0.62	-0.96

Click cells to compare fundamentals

About Unity Biotechnology Financial Statements

Unity Biotechnology investors use historical fundamental indicators, such as Unity Biotechnology's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unity Biotechnology. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	37.7 M	35.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC